Innoviva ROE 2006-2019 | INVA

Current and historical return on equity (ROE) values for Innoviva (INVA) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Innoviva ROE for the three months ending September 30, 2019 was 168.69%.
Innoviva ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2019-09-30 $0.38B $0.28B 168.99%
2019-06-30 $0.38B $0.25B 307.63%
2019-03-31 $0.40B $0.20B 1666.67%
2018-12-31 $0.40B $0.16B -499.68%
2018-09-30 $0.19B $-0.11B -105.70%
2018-06-30 $0.17B $-0.16B -80.10%
2018-03-31 $0.15B $-0.21B -60.25%
2017-12-31 $0.13B $-0.24B -48.86%
2017-09-30 $0.10B $-0.22B -33.47%
2017-06-30 $0.09B $-0.30B -27.22%
2017-03-31 $0.07B $-0.33B -20.31%
2016-12-31 $0.06B $-0.35B -16.32%
2016-09-30 $0.04B $-0.37B -10.58%
2016-06-30 $0.02B $-0.36B -5.18%
2016-03-31 $-0.01B $-0.36B 1.51%
2015-12-31 $-0.02B $-0.34B 6.56%
2015-09-30 $-0.04B $-0.32B 14.55%
2015-06-30 $-0.06B $-0.29B 23.09%
2015-03-31 $-0.11B $-0.26B 51.85%
2014-12-31 $-0.17B $-0.22B 198.24%
2014-09-30 $-0.20B $-0.19B -448.62%
2014-06-30 $-0.23B $-0.19B -130.11%
2014-03-31 $-0.20B $0.26B -82.21%
2013-12-31 $-0.17B $0.30B -84.26%
2013-09-30 $-0.15B $0.33B -91.10%
2013-06-30 $-0.14B $0.09B -109.88%
2013-03-31 $-0.14B $0.09B -91.95%
2012-12-31 $-0.02B $0.16B -13.77%
2012-09-30 $-0.02B $0.17B -34.16%
2012-06-30 $-0.02B $0.19B -163.27%
2012-03-31 $-0.01B $0.01B 18.08%
2011-12-31 $-0.12B $-0.09B 219.91%
2011-09-30 $-0.10B $-0.06B 268.49%
2011-06-30 $-0.09B $-0.04B 154.39%
2011-03-31 $-0.08B $-0.03B 105.99%
2010-12-31 $-0.08B $-0.02B 83.58%
2010-09-30 $-0.09B $-0.14B 61.16%
2010-06-30 $-0.09B $-0.13B 58.37%
2010-03-31 $-0.09B $-0.11B 55.97%
2009-12-31 $-0.09B $-0.19B 50.97%
2009-09-30 $-0.08B $-0.18B 51.55%
2009-06-30 $-0.08B $-0.16B 55.42%
2009-03-31 $-0.08B $-0.14B 64.34%
2008-12-31 $-0.09B $-0.14B 81.21%
2008-09-30 $-0.11B $-0.13B 112.69%
2008-06-30 $-0.12B $-0.11B 157.42%
2008-03-31 $-0.14B $-0.09B 261.68%
2007-12-31 $-0.16B $-0.07B 617.48%
2007-09-30 $-0.16B $-0.04B -2523.08%
2007-06-30 $-0.17B $-0.02B -422.36%
2007-03-31 $-0.17B $0.02B -219.14%
2006-12-31 $-0.17B $0.06B -150.57%
2006-09-30 $-0.17B $0.09B -155.25%
2006-06-30 $-0.17B $0.13B -153.85%
2006-03-31 $-0.16B $0.16B -143.11%
2005-12-31 $-0.14B $0.06B -126.27%
Sector Industry Market Cap Revenue
Basic Materials Gold Miners $1.461B $0.261B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Barrick Gold (GOLD) Canada $31.911B 43.78
Franco-Nevada (FNV) Canada $19.920B 71.86
Newcrest Mining (NCMGY) Australia $16.849B 0.00
Agnico Eagle Mines (AEM) Canada $14.488B 80.47
Kirkland Lake Gold (KL) Canada $9.106B 18.18
AngloGold Ashanti (AU) South Africa $8.455B 0.00
Royal Gold (RGLD) United States $7.397B 61.62
Sibanye Gold (SBGL) South Africa $6.333B 0.00
Kinross Gold (KGC) Canada $5.642B 20.45
Gold Fields (GFI) South Africa $5.080B 0.00
Yamana Gold (AUY) Canada $3.498B 28.31
Alamos Gold (AGI) Canada $2.194B 37.40
Pretium Resources (PVG) Canada $1.942B 22.30
Harmony Gold Mining (HMY) South Africa $1.916B 0.00
Osisko Gold Royalties (OR) Canada $1.494B 43.14
Iamgold (IAG) Canada $1.412B 0.00
Acacia Mining (ABGLF) United Kingdom $1.267B 28.09
Eldorado Gold (EGO) Canada $1.170B 0.00
DRDGOLD (DRD) South Africa $0.407B 0.00
Gold Reserve (GDRZF) United States $0.159B 0.00
Jaguar Mining (JAGGF) Canada $0.134B 0.00